American heart journal plus : cardiology research and practice · 2026
Real-world long-term outcomes of clopidogrel-based dual antiplatelet therapy post-drug-eluting stent implantation in all comers patients: A retrospective evaluation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Parikh Rohan, Langade Jayshree, Langade Deepak
Аннотация
STUDY OBJECTIVE: The objective of this study was to describe the real-world clinical outcomes among patients receiving clopidogrel-based dual antiplatelet therapy following PCI with drug-eluting stents.
DESIGN: This was a retrospective study. Outcomes were assessed by clopidogrel-aspirin DAPT, lipid-lowering therapy, and stent type.
SETTING: Tertiary care cardiology centre in India to evaluate real-world outcomes following PCI with drug-eluting stents (DES) in all patients.
PARTICIPANTS: The study included 1039 PCI-DES patients.
INTERVENTIONS: Clopidogrel-aspirin DAPT.
MAIN OUTCOME MEASURES: Analyses covered event rates, DAPT duration, repeat interventions, and LVEF. Subgroups were compared by age, sex, infarct type, stent type, and LDL-C targets.
RESULTS: Of 1039 patients, 712 had STEMI and 327 had other cardiac conditions. A total of 1349 DES were implanted, mostly sirolimus stents (63.7%). Clopidogrel-based DAPT was very safe, with a MACE rate of 0.29%, slightly higher in older patients (≥55 years), those with ≥4 stents, and those with reduced/unimproved LVEF. Rosuvastatin monotherapy achieved LDL-C < 100 mg/dL with minimal events. Stent type did not affect outcomes, with low repeat interventions (3.4% same vessel, 3.1% other vessels).
CONCLUSION: Clopidogrel with rosuvastatin was safe, effective, and consistent post-PCI, with low events and outcomes independent of stent type.
DESIGN: This was a retrospective study. Outcomes were assessed by clopidogrel-aspirin DAPT, lipid-lowering therapy, and stent type.
SETTING: Tertiary care cardiology centre in India to evaluate real-world outcomes following PCI with drug-eluting stents (DES) in all patients.
PARTICIPANTS: The study included 1039 PCI-DES patients.
INTERVENTIONS: Clopidogrel-aspirin DAPT.
MAIN OUTCOME MEASURES: Analyses covered event rates, DAPT duration, repeat interventions, and LVEF. Subgroups were compared by age, sex, infarct type, stent type, and LDL-C targets.
RESULTS: Of 1039 patients, 712 had STEMI and 327 had other cardiac conditions. A total of 1349 DES were implanted, mostly sirolimus stents (63.7%). Clopidogrel-based DAPT was very safe, with a MACE rate of 0.29%, slightly higher in older patients (≥55 years), those with ≥4 stents, and those with reduced/unimproved LVEF. Rosuvastatin monotherapy achieved LDL-C < 100 mg/dL with minimal events. Stent type did not affect outcomes, with low repeat interventions (3.4% same vessel, 3.1% other vessels).
CONCLUSION: Clopidogrel with rosuvastatin was safe, effective, and consistent post-PCI, with low events and outcomes independent of stent type.